SCHEMBL3369038

SCHEMBL3369038

CC(C)(C)C1CC(=O)OC1=O

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8853723 1.00 SMN1; SMN2 (0.33) SMN1; SMN2ALDH1A1TSHR
SCHEMBL3373990 1.00 SMN1; SMN2 (0.33) SMN1; SMN2ALDH1A1TSHR
SCHEMBL19601183 0.80 ALDH1A1 (0.33) SMN1; SMN2ALDH1A1TSHR
SCHEMBL19356247 0.79 ALDH1A1 (0.35) ALDH1A1TSHR
SCHEMBL15631557 0.79
SCHEMBL14882817 0.79 ALDH1A1 (0.32) ALDH1A1TSHR
SCHEMBL11753823 0.77 SMN1; SMN2 (0.31) SMN1; SMN2
SCHEMBL18193404 0.77 CA1 (0.37) TSHR
SCHEMBL10358513 0.77
SCHEMBL14883033 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112752800-B Process for preparing a crude surface-treated filler material product OMYA国际股份公司 2026-05-19 CN disclosed
US-12630438-B2 Process for producing precipitated calcium carbonate in the presence of natural ground calcium carbonate OMYA INTERNATIONAL AG (CH) 2026-05-19 US disclosed
US-12624482-B2 Nonwoven fabrics comprising polylactic acid and surface-treated calcium carbonate OMYA INTERNATIONAL AG (CH) 2026-05-12 US disclosed
US-12617934-B2 Low noise biodegradable breathable films OMYA INTERNATIONAL AG (CH) 2026-05-05 US disclosed
EP-4702083-A1 POLYPROPYLENE (PP) - CACO3 MASTERBATCH IN PET FIBERS Omya International AG (CH) 2026-03-04 EP disclosed
US-12486379-B2 Use of a porous filler for reducing the gas permeability of an elastomer composition OMYA INTERNATIONAL AG (CH) 2025-12-02 US disclosed
EP-4097283-B1 NONWOVEN FABRICS COMPRISING POLYLACTIC ACID AND SURFACE-TREATED CALCIUM CARBONATE OMYA INT AG (CH) 2025-06-25 EP disclosed
EP-4175998-B1 LOW NOISE BIODEGRADABLE BREATHABLE FILMS OMYA INT AG (CH) 2025-03-19 EP disclosed
US-20250051539-A1 CALCIUM CARBONATE-COMPRISING MATERIAL WITH HIGH BIO-BASED CARBON CONTENT FOR POLYMER FORMULATIONS OMYA INTERNATIONAL AG (CH) 2025-02-13 US disclosed
US-20240409719-A1 PRECIPITATED CALCIUM CARBONATE WITH HIGH BIO-BASED CARBON CONTENT FOR POLYMER FORMULATIONS OMYA INTERNATIONAL AG (CH) 2024-12-12 US disclosed
EP-1599496-A2 HEPATITIS C INHIBITOR PEPTIDE ANALOGS Boehringer Ingelheim International GmbH (DE) 2005-11-30 EP disclosed
US-6908901-B2 Hepatitis C inhibitor peptide analogs BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) 2005-06-21 US disclosed
WO-2004101602-A2 HEPATITIS C INHIBITOR PEPTIDE ANALOGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-11-25 WO disclosed
US-20040224900-A1 Hepatitis C inhibitor peptide analogs BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-11-11 US disclosed
EP-0493767-B1 Synergistic combination for treating herpes infections BIO MEGA BOEHRINGER INGELHEIM (CA) 1997-03-19 EP disclosed
US-5484771-A RIBONUCLEOTIDE REDUCTASE INHIBITORS BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1996-01-16 US disclosed
EP-0461546-B1 Antiherpes peptide derivatives having a 1,4-dioxo-C4 N-terminus BIO MEGA BOEHRINGER INGELHEIM (CA) 1995-03-22 EP disclosed
US-5380727-A Antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative BIO-MEGA, INC. (CA) 1995-01-10 US disclosed
EP-0493767-A2 Synergistic combination for treating herpes infections BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1992-07-08 EP disclosed
EP-0461546-A2 Antiherpes peptide derivatives having a 1,4-dioxo-C4 N-terminus BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1991-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624482-B2 Nonwoven fabrics comprising polylactic acid and surface-treated calcium carbonate STIM1, CA2, CACNA2D4 SMN1; SMN2 836/4885ALDH1A1 4227/4885TSHR 4718/4885
US-20040224900-A1 Hepatitis C inhibitor peptide analogs RNASE1, HAVCR2, CTRL SMN1; SMN2 4347/4885ALDH1A1 2344/4885TSHR 2135/4885
US-12617934-B2 Low noise biodegradable breathable films COL2A1, COL1A1, CA7 SMN1; SMN2 1542/4885ALDH1A1 3438/4885TSHR 2259/4885
US-12630438-B2 Process for producing precipitated calcium carbonate in the presence of natural ground calcium carbonate TMCO1, CALCOCO2, CACNA2D1 SMN1; SMN2 504/4885ALDH1A1 4634/4885TSHR 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.